A study by Pullarkat et al. reported on a phase I dose-escalation NCT03181126 study that combined venetoclax with low-dose navitoclax, a BCL-XL/BCL2 dual inhibitor in patients with relapsed/refractory ALL or lymphoblastic lymphoma. The gene discussed is BCL2; the disease is acute lymphoblastic leukemia.